GlassScriptPhysician profile
Catharine Tabb
NPI 1184600652
$880.84
in general payments reported to CMS, 2019-2025
18 companies · $59.32 in 2025
The $59.32 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $145 · 2025: $59.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $136.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.28 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $106.79 | 2019-2020 | |
| Novo Nordisk INC | $79.75 | 2019-2020 | |
| Glaxosmithkline, LLC. | $67.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.27 | 2019 | |
| Amarin Pharma, INC. | $64.45 | 2019-2020 | |
| Lilly USA, LLC | $58.26 | 2019 | |
| Merck Sharp & Dohme LLC | $53.54 | 2019 | |
| Pfizer INC. | $29.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $20.20 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.14 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.14 | 2019 | |
| Dynavax Technologies Corporation | $12.97 | 2019 | |
| Circassia INC. | $11.84 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $11.35 | 2019 | |
| Allergan, INC. | $11.32 | 2019 | |
| Abbvie INC. | $11.01 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catharine Tabb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.